A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2013

Conditions
Symptomatic Waldenstroms Macroglobulinaemia
Interventions
DRUG

Belimumab

"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."

Trial Locations (2)

3002

RECRUITING

The Peter MacCallum Cancer Centre, Melbourne

3181

RECRUITING

Alfred Health, Melbourne

Sponsors
All Listed Sponsors
collaborator

Human Genome Sciences Inc.

INDUSTRY

lead

Cancer Trials Australia

OTHER